Compare immunoadsorption vs plasma exchange for Guillain-Barré
Treatments studied
Part of Brain & nervous system, Immune system & allergy clinical trials.
This study tests whether immunoadsorption works as well as plasma exchange to improve symptoms in people with Guillain-Barré syndrome. The goal is to find which treatment helps recovery and is safer for patients.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a diagnosis of Guillain-Barré syndrome (GBS) based on standard medical criteria
- You must be 18 years old or older
- You should not have a clear ongoing body-wide infection (by symptoms or lab tests like high C-reactive protein or a nitrite-positive urine infection)
- You should not have taken an ACE inhibitor blood pressure/heart medicine within 1 week before starting treatment
- You must not have other reasons you cannot safely receive immunoadsorption or plasma exchange
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This is an observational study that looks at people who were suspected to have Guillain-Barré syndrome and were cared for at University Hospital of Basel in the past. It does not test a new treatment—researchers review existing care to learn more about this condition.
This Phase 2 study compares a blood-cleansing treatment (immunoadsorption) with standard immune-boosting treatment (intravenous immunoglobulins) for chronic inflammatory demyelinating polyneuropathy (CIDP). It may help people whose steroid treatment did not work well, or who cannot take steroids.
This trial compares two blood-based treatments for Guillain-Barré syndrome: one that filters antibodies from the blood (immunoadsorption) and one that uses donated antibodies (IVIG). Both aim to reduce nerve damage and speed up recovery, and researchers want to see which works better.
This trial tests whether an experimental drug called efgartigimod (given as an infusion) can help people with Guillain-Barré syndrome recover faster. It is for adults who recently developed symptoms and have significant weakness that affects their walking.
This trial tests a new medicine called efgartigimod for people with Guillain-Barré syndrome (GBS), a condition where the immune system attacks the nerves. The medicine aims to reduce the immune attack and help you recover faster. It is for people who started having GBS symptoms within the last 2 weeks and have moderate to severe symptoms.
This study tests a new investigational medicine called empasiprubart when added to the standard IVIg treatment for people with Guillain-Barré syndrome. It aims to see if adding this medicine can help improve recovery compared to IVIg alone.
Hear when a new GBS trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.